Oramed Pharmaceuticals (ORMP) Stock Chart & Stock Price History $2.16 -0.02 (-0.92%) As of 03:59 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oramed Pharmaceuticals Stock Price Performance The Oramed Pharmaceuticals (ORMP) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 15.63%, with a year-to-date return of -10.74%. In the past month, the stock has decreased 2.70%, reflecting recent market activity. As of the latest close, Oramed Pharmaceuticals traded at $2.18 with a market cap of $89.22 million and volume of 18,026 shares. Five years ago, the stock traded at $3.35, representing a 35.52% decrease over that period. At the time, it had a market cap of $80.32 million and a volume of 109,375 shares. Receive ORMP Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance0.00%1 Month Performance-2.70%3 Month Performance+2.86%Year-To-Date Performance-10.74%1 Year Performance-15.63%5 Year Performance-35.52% ORMP Stock Chart for Monday, July, 7, 2025 ORMP Chart by TradingView Oramed Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/04/2025$2.18$2.18$2.20$2.1618,026 shs$89.22 million07/03/2025$2.16$2.18+1.11%$2.20$2.1618,026 shs$89.22 million07/02/2025$2.10$2.16+2.86%$2.19$2.1247,183 shs$88.24 million07/01/2025$2.25$2.10-6.67%$2.20$2.10117,830 shs$85.79 million06/30/2025$2.15$2.25+4.65%$2.25$2.11149,028 shs$91.91 million06/27/2025$2.17$2.15-0.92%$2.18$2.1059,111 shs$87.83 million06/26/2025$2.18$2.17-0.46%$2.19$2.1432,014 shs$88.64 million06/25/2025$2.17$2.18+0.46%$2.19$2.1326,985 shs$89.05 million06/24/2025$2.11$2.17+2.84%$2.21$2.07157,636 shs$88.64 million06/23/2025$2.13$2.11-0.94%$2.25$2.06141,792 shs$86.19 million Get the Latest News and Ratings for ORMP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 06/20/2025$2.15$2.13-0.93%$2.17$2.0696,723 shs$87.01 million06/19/2025$2.15$2.15$2.20$2.1435,339 shs$87.83 million06/18/2025$2.16$2.15-0.46%$2.20$2.1435,339 shs$87.83 million06/17/2025$2.16$2.16$2.17$2.1423,221 shs$88.24 million06/16/2025$2.13$2.16+1.41%$2.17$2.1518,336 shs$88.24 million06/13/2025$2.24$2.13-4.91%$2.23$2.1242,954 shs$87.01 million06/12/2025$2.23$2.24+0.45%$2.26$2.1828,302 shs$91.50 million06/11/2025$2.23$2.23$2.27$2.2326,396 shs$91.10 million06/10/2025$2.23$2.23$2.28$2.2237,029 shs$91.10 million06/09/2025$2.22$2.23+0.45%$2.26$2.1841,289 shs$91.10 million06/06/2025$2.15$2.22+3.26%$2.25$2.0786,429 shs$90.69 million Related Companies Terns Pharmaceuticals Stock Chart Humacyte Stock Chart Prothena Stock Chart Heron Therapeutics Stock Chart Amarin Stock Chart Prime Medicine Stock Chart SNDL Stock Chart Aquestive Therapeutics Stock Chart Citius Oncology Stock Chart Olema Pharmaceuticals Stock Chart Receive ORMP Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ORMP) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
